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DOI 10.1016/j.immuni.2010.11.025SUMMARY DCs could influence SLE in several ways: presentation of self-Dendritic cells (DCs) initiate and control the adaptive
immune response against infections. However, their
contributions to the anti-self adaptive immune
response in autoimmune disorders like systemic
lupus erythematosus are uncertain. By constitutively
deleting DCs in MRL.Faslpr mice, we show that they
have complex roles in murine lupus. The net effect
of DC deletion was to ameliorate disease. DCs were
crucial for the expansion and differentiation of
T cells but, surprisingly, not required for their initial
activation. Correspondingly, kidney interstitial infil-
trates developed in the absence of DCs, but failed
to progress. DC deletion concomitantly decreased
inflammatory and regulatory T cell numbers. Unex-
pectedly, plasmablast numbers and autoantibody
concentrations depended onDCs, in contrast to total
serum immunoglobulin concentrations, suggesting
aneffect ofDCsonextrafollicular humoral responses.
These findings reveal that DCs operate in unantici-
pated ways in murine lupus and validate them as
a potential therapeutic target in autoimmunity.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease with diverse clinical manifestations. Studies targeting
B cells in both mice and humans have demonstrated the impor-
tance of B cells in promoting immune activation and tissue
damage in lupus, partly by antibody-independent mechanisms
(Chan et al., 1999a, 1999b; Looney, 2010). Activated T cells
also play important roles, as indicated by the fact that disease
is substantially reduced, though not eliminated, when T cells
are absent or inhibited (Jabs et al., 1992; Jevnikar et al., 1994).
In contrast, the role of dendritic cells (DCs) in the pathogenesis
of SLE is largely unknown.
The contributions of DCsmay be complicated, in part because
there are numerous subsets of them (Geissmann et al., 2010).Iantigen to autoreactive T cells; secretion of proinflammatory
cytokines; and promotion of B cell autoantibody production,
either directly or indirectly. DCs are widely considered to be crit-
ical for initiating T cell responses in infections (Mellman and
Steinman, 2001). Based on this notion, it could be assumed
that they are the primary antigen-presenting cells (APCs) to
induce T cell autoimmunity. However, depending on their activa-
tion state, DCsmight also support peripheral T cell self-tolerance
instead of T cell immunity (Hawiger et al., 2001). In one (Ohn-
macht et al., 2009) but not another (Birnberg et al., 2008) study,
constitutive deletion of DCs on a nonautoimmune background
elicited autoimmunity.
DCs could also boost disease by secreting inflammatory cyto-
kines. For example, peripheral blood T cells from SLE patients
produce larger amounts of IFN-g than those from healthy individ-
uals (Harigai et al., 2008), and genetic deletion of IFN-g or its
receptor in MRL.Faslpr mice ameliorates disease (Balomenos
et al., 1998; Schwarting et al., 1998). Activated cDCs secrete
IL-12-p70, which elicits the production of IFN-g by NK and
T cells and promotes the differentiation of naive T helper cells
into Th1 cell effectors. Furthermore, type I IFNs produced by
pDCs lead to cDC maturation and lower the activation threshold
for Toll-like receptor agonists.
Aside from priming of CD4+ T cells that in turn promote the
anti-self B cell response, DCs could also affect the autoreactive
B cell response directly. DCs possess a nondegradative antigen
uptake pathway that facilitates interaction of the B cell receptor
with whole antigen on the DC surface (Qi et al., 2006; Bergtold
et al., 2005). The importance of this mechanism has yet to be
elucidated, but the finding implies enhancement of humoral
responses by direct DC-B cell interactions. Moreover, DCs are
important sources of B cell-activating factor of the TNF family
(BAFF) and a proliferation-inducing ligand (APRIL), which are
implicated in promoting B cell survival and plasmablast differen-
tiation, and in particular regulating self-tolerance by influencing
survival of autoreactive anergic B cells (Treml et al., 2009).
The relative importance of DCs compared to other APCs in
generating anti-self T cell immunity cannot necessarily be in-
ferred from their dominance in inducing antipathogen T cell
immunity because of potential roles of B cells as APCs. Although
classically it was thought that B cells mainly contribute to lupusmmunity 33, 967–978, December 22, 2010 ª2010 Elsevier Inc. 967
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DCs in Lupusexpression by production of pathogenic autoantibodies,multiple
studies inmice and patients have suggested that APC function of
B cells is critical in promoting disease. When B cells are depleted
genetically, T cell activation is inhibited in the murine models of
lupus MRL-MpJ-Faslpr (called MRL.Faslpr hereafter) and Fas-
intact MRL (Chan et al., 1999b). This function of B cells is anti-
body independent, as shown by the fact that T cell activation is
mainly intact in MRL.Faslpr mice that lack soluble antibodies
but have B cells (Chan et al., 1999a). Most notably, B cell-
deficient lupus-prone mice have virtually no residual disease,
such as nephritis, vasculitis, or dermatitis.
Given the functions of DCs in both promoting T cell immunity
as well as establishing T cell tolerance, along with the uncertain
importance of their APC function relative to B cells in activating
autoreactive T cells, it is hard to predict how DCs influence
disease. However, some clues that DCs are key players in auto-
immunity come from studies of hyperactive or unregulated DCs
in C57BL/6 mice. The adoptive transfer of bone marrow-derived
DCs deficient for suppressor of cytokine signaling-1 (SOCS1)
(Hanada et al., 2003) or DCs bearing the Sle3 susceptibility locus
(Zhu et al., 2005) into C57BL/6 mice led to marked production of
anti-nuclear antibodies (ANA) when coupled with LPS coadmin-
istration. C57BL/6 mice with a DC-specific deletion of Fas
showed ANA generation and liver lesions (Stranges et al.,
2007). However, although these studies have provided insights,
they demonstrate the potential of DCs to cause disease when
they are intentionally and selectively dysregulated, rather than
what their nonredundant functions are in a polygenic, sponta-
neous autoimmunedisease setting. The latter requires a subtrac-
tive approach by deleting DCs in a murine polygenic model of
lupus.
Here, we sought to delete DCs in the MRL.Faslpr model of
lupus. Several systems for DC deletion are available, each with
different advantages (recently reviewed in Bar-On and Jung,
2010). We chose a constitutive deletion approach as most
appropriate for the chronic, progressive nature of lupus to
answer three related questions. (1) What is the overall effect of
DC function in lupus? (2) At what stages of lupus pathogenesis
are DCs required? (3) In what way do DCs affect the sponta-
neous T and B cell responses in lupus?RESULTS
DC Depletion in Lupus-Prone Mice
We generated DC-deficient mice (called CD11c:DTA hereafter)
on the MRL.Faslpr lupus-prone genetic background. Analogous
to the situation in human SLE, multiple genes with disease-asso-
ciated alleles are expressed in a variety of cell lineages and act in
concert to produce disease in MRL mice (Cheung et al., 2009).
The Faslpr allele further contributes by accelerating and accentu-
ating disease progression. We then compared CD11c:DTA mice
with their littermate controls. Deletion efficiency of DCs was as-
sessed by FACS analysis (Figure S1 available online). In
CD11c:DTA mice, more than 92% of cDCs and 86% of pDCs
were depleted in the spleen (Table S1). In mesenteric lymph no-
des, bone marrow, and thymus (only cDCs) depletion had about
the same efficiency (Table S1). Inspection of FACS plots (Fig-
ure S1) revealed that in CD11c:DTA mice, remaining events968 Immunity 33, 967–978, December 22, 2010 ª2010 Elsevier Inc.were on the border of the drawn gates and thus many of them
may represent background rather than bona fide residual DCs.
The effect of constitutive DC depletion on central T cell toler-
ance is controversial (Birnberg et al., 2008; Ohnmacht et al.,
2009). In our model, negative selection of T cells was unimpaired
as determined by normal deletion of T cell receptor Vb5- and
Vb11-bearing T cell subsets (data not shown). Metallophilic
and marginal zone macrophages were not deleted in
CD11c:DTA mice (Figure S1) in contrast to what has been re-
ported for the inducible CD11c-DTR system (Probst et al.,
2005). Preautoimmune 5-week-old CD11c:DTA mice showed
an expansion of F4/80+ macrophages (spleen) and neutrophils
(spleen and axillary lymph nodes), which was previously
described in constitutively DC-deficient mice on nonautoim-
mune backgrounds (Figure S1; Birnberg et al., 2008; Ohnmacht
et al., 2009). Together, these findings indicate that the
CD11c:DTA system efficiently deletes DCs on the MRL.Faslpr
background without affecting thymic negative selection of
T cells.
DCs Promote Glomerular and Interstitial Nephritis
Renal involvement becomes clinically apparent in 50% of SLE
patients. In most MRL.Faslpr mice, it is present at 16 weeks of
age. To assess whether DCs contribute to nephritis, we scored
severity of glomerular (GN) and interstitial nephritis (IN) in the
peritubular and perivascular region. In all locations inflammation
was markedly reduced (Figure 1A). In particular we found
a dramatic decrease in the number and size of perivascular infil-
trates, which we separately quantitated by calculating the
percentage area of the infiltrates (Figures 1B and 1C). We next
tested whether the histopathological differences between
CD11c:DTA and control mice reflected kidney function. Indeed,
DC-deficient mice had markedly less proteinuria than littermate
controls, reaching only a maximum score of 1+ (Figure 1D).
These results indicate that DCs contribute to GN and IN in lupus.
However, manyDC-deficientmice still developedmilder forms
of GN and IN. This suggested that either depletion of DCs was
incomplete in the kidneys or that DCs regulate the extent rather
than the occurrence of nephritis. To address the first possibility,
we used immunofluorescence microscopy to detect DCs in
interstitial infiltrates. In control mice a sizable proportion of the
cells in interstitial infiltrates were CD11c+ (Figure 2A). We found
hardly any CD11c+ cells in the residual infiltrates in CD11c:DTA
mice, suggesting that DC deletion in the kidneys was effective
(Figure 2A). Beside DCs, T cells are a major constituent of kidney
infiltrates in MRL.Faslpr mice and human lupus patients. We
asked whether local proliferation of T cells contributed to the
development of infiltrates. Indeed,many CD4+ T cells in the inter-
stitial and periglomerular infiltrates were dividing, as demon-
strated by Ki67 staining and 5-bromo-2-deoxyuridine (BrdU)
staining after a 2 hr BrdU single-time pulse (Figure 2B). We could
also detect proliferating CD11c+ cells (Figure 2B), consistent
with the notion that DCs can undergo a limited number of divi-
sions in nonlymphoid tissues. Thus, DCs are instrumental in
the marked expansion of kidney lesions but are not required
for their establishment. Infiltrate expansion involves local prolif-
eration of T cells in addition to their recruitment.
Conventionally, immune complexes deposited in glomeruli are
believed to be the primary mediators of GN. We used
Figure 1. Ameliorated Lupus Nephritis in DC-Deficient
Mice
(A) Glomerular and interstitial (peritubular and perivascular)
renal disease were scored from 0 to 4 for control and
CD11c:DTA mice. Each dot represents an individual mouse.
Horizontal lines represent the median.
(B) The area of perivascular infiltrates expressed as
a percentage of the total kidney section area is plotted for
control (n = 24) and CD11c:DTA (n = 14) mice. Data are repre-
sented as mean ± SEM.
(C) Representative H&E-stained kidneys sections (left, scale
bars represent 2 mm) and magnified details of white bordered
area of both kidney sections (right, scale bars represent
500 mm). Arrows indicate perivascular infiltrates.
(D) Proteinuria for control and CD11c:DTA mice. Each dot
represents an individual mouse. Horizontal lines represent
the median.
Statistics were calculated by two-tailed Mann-Whitney U test.
*p < 0.05; ***p < 0.001.
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DCs in Lupusimmunofluorescence microscopy to determine the amount of
immune complex deposition in the glomeruli. Although GN and
IN were ameliorated in the absence of DCs, we did not detect
any differences in complement factor C3 or IgG deposition in
the glomeruli (Figure 2C and data not shown). These results
imply that immune complexes per se are insufficient to cause
GN and IN and that end-organ responses to the deposits are
a critical factor. Collectively, these findings demonstrate that
although DCs are not required for the initial development of GN
and IN, they play a substantial role in the progression of nephritis.
DCs Other than LCs Contribute to Dermatitis
Dermatitis is a commonmanifestation of human SLE and among
murine lupus models is uniquely found in the MRL and
MRL.Faslpr strains. We assessed whether DC depletion would
affect dermatitis. Because MRL.Faslpr females develop derma-
titis more frequently than males, we restricted our analysis to
females. 13 of 20 control mice developed dermatitis but only 1
of 12 CD11c:DTA mice was affected (Figure 3A, p < 0.01),
demonstrating that DCs are important for the development of
dermatitis.
There are at least four DC subpopulations in the skin: Langer-
hans cells (LCs) in the epidermis and pDCs, CD11b+ DCs, and
CD11bCD103+Langerin+ DCs in the dermis (Heath and Car-
bone, 2009; Nestle et al., 2009). During inflammation the skin
can also be infiltrated by iNOS-producing DCs (De Trez et al.,
2009). Reports differ on whether DTA expression in CD11c+ cells
results in ablation of LCs (Birnberg et al., 2008; Ohnmacht et al.,
2009). In our model, LCs were depleted in most areas of the
epidermal sheets that we examined, with only rare small clusters
of residual cells (Figure 3B). To determine whether the markedImmunity 33, 9reduction in dermatitis prevalence was due to the
loss of LCs alone versus other DC types, we gener-
ated MRL.Faslpr F2 mice that express DTA under
the control of the human Langerin promoter
(Kaplan et al., 2005). In these mice, as reported
on the FVB/N and C57BL/6 backgrounds (Igyarto
et al., 2009; Kaplan et al., 2005), LCs are deleted
(Figure 3C), but other known populations of DCs,including Langerin+ dermal DCs, are unaffected. There was no
substantial difference in the prevalence of dermatitis between
Langerin-DTA MRL.Faslpr F2 mice and littermate controls (Fig-
ure 3D). We conclude that LCs are dispensable but that other
DC types contribute considerably to dermatitis development.
Impaired IgG and IgM Autoantibody Formation
in DC-Deficient Mice
To understand the mechanisms by which DCs contribute to end-
organ damage in lupus, we asked how DC deletion affects the
anti-self adaptive immune response. First we examined the
adaptive humoral immune system. We observed slight drops in
serum IgG2b and IgG3 concentrations and a slight increase for
IgA in DC-deficient mice, but total serum IgG and IgM concentra-
tions were unchanged (Figure 4A). Despite the similar overall IgG
and IgM concentrations, we considered it possible that DCs
have an effect on the production of autoantibodies, many of
which derive from short-lived plasmablasts (Hoyer et al., 2004;
William et al., 2002), rather than long-lived plasma cells that
contribute most of the serum Ig (Slifka et al., 1998). To assess
this, we first used the HEp-2 cell-based immunofluorescent
microscopy assay to detect IgG antinuclear and anticytoplasmic
antibodies. Typical for MRL.Faslpr mice, 21 of 24 (87.5%) sera
from control mice produced a homogenous staining pattern,
corresponding to anti-DNA and anti-chromatin IgG (Figures 4B
and 4C). Moreover, 23 of 24 (95.8%) control sera showed equa-
torial staining of mitotic chromatin, indicating specific chromatin
IgG autoantibodies (Figures 4B and 4D). In contrast, only 6 of 14
(42.9%) sera from CD11c:DTA mice generated a homogenous
staining pattern, with the emergence of additional patterns
such as nucleolar and cytoplasmic that were rarely seen in67–978, December 22, 2010 ª2010 Elsevier Inc. 969
Figure 2. Local Proliferation of CD4+ T Cells and DCs in Kidney Infil-
trates
(A) Staining for DAPI (blue) to locate nuclei and CD11c (green) to identify DCs
on kidney cryosections. Shown are perivascular infiltrates. Data are represen-
tative for kidneys from three mice of each type.
(B) Confocal images of kidney infiltrates. CD4+ T cells and DCs were detected
by staining for CD4 (green) and CD11c (blue), respectively. Proliferating cells
were identified by staining for Ki67 or BrdU after a 2 hr BrdU i.p. single-time
pulse (red). The bottom left image shows a periglomerular infiltrate and the
other images perivascular infiltrates. Arrows indicate examples of proliferating
cells. Data are representative for kidneys from threewild-typeMRL.Faslprmice.
(C) Staining for complement C3 (white) to detect glomerular immune deposits.
Data are representative for kidneys from 10 mice of each type.
Scale bars represent 50 mm.
Figure 3. DCs Other than LCs Contribute to Dermatitis
(A) Percentage of female control (n = 20) and CD11c:DTA (n = 12) mice with
dermatitis at 16 weeks of age.
(B) Epidermal sheets from control and CD11c:DTA mice were stained for
I-A/I-E (mouse MHC class II) to identify LCs (red). The images in the middle
and on the right side represent two visual fields from the same sample to better
illustrate that, rarely, small Langerhans cell clusters were detectable in
CD11c:DTA mice. Data are representative of epidermal sheets from three
mice of each type. Scale bar represents 50 mm.
(C) Epidermal sheets from control and Langerin-DTA mice stained as in (B).
Data are representative of epidermal sheets from three mice of each type.
Scale bar represents 50 mm.
(D) Percentage of female control (n = 19) and Langerin-DTA (n = 16) mice with
dermatitis until death. Themean survival of Langerin-DTAmicewas 145.2 days
and of control mice 141.7 days.
Statistics were calculated by Fisher’s exact test. **p < 0.01.
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DCs in LupusDC-intact animals (Figure 4C, p < 0.01); similarly, only 9 of 14
(64.3%) CD11c:DTA sera produced IgG autoantibodies that
bind mitotic chromatin (Figure 4D, p < 0.05). In a separate cohort
of less backcrossed mice (CD11c-Cre MRL.Faslpr BC10 3
Rosa26-eGFP-DTA MRL.Faslpr BC5), which developed a milder
disease (data not shown), half of the sera from control mice970 Immunity 33, 967–978, December 22, 2010 ª2010 Elsevier Inc.demonstrated a homogenous staining pattern, but none of the
sera from DC-deficient mice did so (Figure S2). These results
indicate that DCs influence both autoantibody concentrations
and composition.
To quantitate serum IgG autoantibodies against nucleosomes
and Sm protein (part of the RNA splicing complex), we per-
formed ELISAs. Both antinucleosome and anti-Sm IgG were
markedly decreased in the absence of DCs (Figure 4E). The
reduction was more pronounced for antinucleosome (95.6%)
than for anti-Sm (54.3%) IgG. To investigate whether the
reduction of IgG autoantibodies was solely the result of impaired
class switching, we measured antinucleosome IgM by ELISA.
We detected considerably less antinucleosome IgM in sera
from DC-deficient mice than in sera from control mice
(68.4%) (Figure 4F). Additionally, we found rheumatoid factor
concentrations, with anti-k as the detection reagent, to be
Figure 4. Impaired Generation of Autoantibodies in the Absence of DCs
(A) Serum Ig isotype concentrations of control (n = 23) and CD11c:DTA (n = 14) mice. Data are represented as mean ± SEM.
(B) Illustration of Hep-2 ANA staining patterns fromMRL.Faslprmice. Arrows indicate the presence (left top) or the absence (right top) ofmitotic chromatin staining.
Scale bar represents 50 mm.
(C and D) ANA staining pattern classified as homogenous, speckled, nucleolar, or cytoplasmic (C) and mitotic chromatin staining classified as positive or
negative (D), produced by sera from control and CD11c:DTA mice. The numbers in the circles indicate the number of total mice analyzed.
(E–G) Serum concentrations of antinucleosome IgG and anti-Sm IgG (E), antinucleosome IgM (F), and rheumatoid factor k (G). Each dot represents an individual
mouse. Horizontal lines represent the median.
Statistics were calculated by either Chi square analysis (C), Fisher’s exact test (D), or two-tailed Mann-Whitney U test (E–G). *p < 0.05, **p < 0.01, ***p < 0.001.
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DCs in Lupusdecreased 84.4% in sera from CD11c:DTA mice (Figure 4G)
compared to controls. Therefore, DCs substantially promote
the generation of antibodies against self-antigens, and particu-
larly against chromatin-containing autoantigens.IPlasmablast Numbers and Class Switching
Are Decreased in the Absence of DCs
Short-lived plasmablasts are a major source of autoantibodies in
MRL.Faslpr mice and in other lupus mouse models (Hoyer et al.,mmunity 33, 967–978, December 22, 2010 ª2010 Elsevier Inc. 971
Figure 5. Reduced Plasmablast Numbers and Class Switching in CD11c:DTA Mice
(A) Number of k light chain antibody-forming cells (AFC) per spleen determined by ELISpots. n = 14 for control mice and n = 13 for CD11c:DTA mice.
(B) Numbers of plasmablasts (CD138+CD44+intracellular-kappahi, after gating on EMATCRb cells) per spleen in control (n = 6) and CD11c:DTA (n = 6) mice. The
pseudo-color plots on the left side illustrate the last two gating steps.
(C) Numbers of B cells (CD22hiCD19hi) per spleen in control (n = 24) and CD11c:DTA (n = 14) mice.
(D) Apoptosis of plasmablasts assessed by staining for active caspase-3.
(E) ELISpot assays for IgG1-, IgG2a-, and IgM-secreting cells in the spleen were performed. Numbers of IgG1 and IgG2a spots were normalized to numbers of
IgM spots to reflect the selective effect on switching that DC deletion might have. n = 14 for control mice and n = 13 for CD11c:DTA mice.
Data are represented as mean ± SEM. Statistics were calculated by two-tailed Mann-Whitney U test. *p < 0.05, **p < 0.01.
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DCs in Lupus2004; William et al., 2002). They originate from B cell responses
at extrafollicular loci, whereas long-lived plasma cells derive
from germinal centers. Consistent with the decrease in autoanti-
body concentrations, the number of splenic antibody forming
cells, which mainly consist of short-lived plasmablasts, was
substantially reduced in DC-deficient mice, as assessed by
ELISpot assays (Figure 5A). We obtained corresponding results
by flow cytometry, identifying plasmablasts as CD138+CD44+
intracellular-kappahi cells (Figure 5B). Importantly, there was
no difference in B cell numbers between DC-deficient and
control mice (Figure 5C), suggesting that DC deletion does not
impair B cell homeostasis. The apoptosis rates of plasmablasts
were similar in both groups (Figure 5D). It is therefore most likely
that the reduced numbers of plasmablasts in CD11c:DTA mice
result from impaired plasmablast generation. The unaltered total
serum IgG and IgM concentrations indicate that long-lived
plasma cells, whichmainly reside in the bonemarrow, were unaf-
fected by the deletion of DCs.
Notably, there was a 23-fold difference for antinucleosome
IgG but only a 3-fold difference for antinucleosome IgM
between CD11c:DTA and control mice (Figures 4E and 4F). A972 Immunity 33, 967–978, December 22, 2010 ª2010 Elsevier Inc.possible explanation for thiswas that polyreactive IgMantibodies
caused more background in the IgM-specific ELISA, partly
obscuring the impact of DC deletion on IgM antinucleosome
formation. Alternatively, it was also possible that there is a
selective effect of DCs on class switching. ELISpots specific for
IgG1, IgG2a, and IgMantibody forming cells revealed that indeed
class switching, as assessed by the ratio of IgG1:IgM and
IgG2a:IgM spots, was partly blocked in splenic plasmablasts
(Figure 5E) in CD11c:DTA mice. Taken together, these results
demonstrate that DC deletion impairs plasmablast generation
along with class switching. As a consequence, serum IgM, and
even more so IgG, autoantibody concentrations are reduced.
DCs Are Critical for T Cell Expansion but Not Activation
Next, we investigated the effect of DC deletion on T cell immunity
in lupus. At 16 weeks of age, MRL.Faslpr mice develop a severe
lymphadenopathy and splenomegaly caused by the accumula-
tion of T cells. Those T cells in large part express the B cell
marker B220 and are negative for the coreceptors CD4 and
CD8. Double-negative T cells are thought to be derived from
activated CD8+ T cells, which in lpr mice cannot be removed in
Figure 6. DCs Are Critical for T Cell Expansion but Not Activation
(A) Weight of spleens and the two largest axillary lymph nodes of control (black bars) and CD11c:DTA (white bars) mice.
(B and C) Cell numbers of control (black bars) and CD11c:DTA (white bars) mice for total T cells (B) (spleen and biggest left axillary lymph node) or the T cell
subsets CD4+, CD8+, CD4+CD8+, and double-negative (C) (spleen). Panels on the left show sample flow cytometric data.
(D) T cell proliferation determined by Ki67 staining. The histogram on the left shows representative examples of Ki67 staining of gated EMATCRb+ cells.
(E) CD44 and CD62L staining of CD4+ T cells of 16-week-old control (black bars) and CD11c:DTA (white bars) mice to identify naive (CD44loCD62Lhi) and
activated-memory (CD44hi) subpopulations. Representative flow cytometric data on gated CD4+ T cells is shown on the left.
Data in bar graphs are represented as mean ± SEM. (A–C) n = 24 for control mice and n = 14 for CD11c:DTA mice. (D–F) n = 12 for control mice and n = 9 for
CD11c:DTA mice. Statistics were calculated by two-tailed Mann-Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001.
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DCs in Lupusa Fas-FasL-dependent fashion (Mehal and Crispe, 1998). They
are considered to be mainly inert. Axillary lymph node weight
was drastically reduced in the absence of DCs (Figure 6A).
Spleen weight was about the same in DC-deficient and control
mice (Figure 6A). On a nonautoimmune background, DC-
deficient mice have a higher average spleen weight than litter-
mate controls because constitutive deletion of DCs leads to
the expansion of macrophages and neutrophils (Birnberg et al.,
2008; Ohnmacht et al., 2009). Thus, a similar spleen weight in
CD11c:DTA and control MRL.Faslpr mice probably reflected
a balance between increased numbers of myeloid cells and
reduced T cell accumulation in DC-deficient mice. Indeed,
FACS analysis confirmed lower T cell numbers in the axillary
lymph nodes and spleen in mice lacking DCs (Figure 6B). Among
theCD4+, CD8+, CD4+CD8+, and double-negative T cell subsets,Ithe double-negative population exhibited the greatest relative
and absolute decrease (Figure 6C). The dampened T cell expan-
sion in the absence of DCswas associatedwith a smaller fraction
of proliferating T cells, as shown by Ki67 staining (Figure 6D).
Surprisingly, the effect of DC deletion on spontaneous CD4+
T cell activation was very modest (Figure 6E). Activated-memory
CD4+ T cells as a percentage of total CD4+ T cells were only
slightly decreased in 16-week-old CD11c:DTA mice compared
to littermate controls. There was no appreciable difference for
naive CD4+ T cells between both groups (Figure 6E), being
very low in both cases. In mice at an early stage of disease
(12 week), there was a small increase in naive CD4+ T cells in
DC-deficient animals, but about 70% of CD4+ T cells still had
an activated-memory phenotype (Figure S3). These observa-
tions are consistent with efficient activation of naive T cellsmmunity 33, 967–978, December 22, 2010 ª2010 Elsevier Inc. 973
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DCs in Lupuseven in the absence of DCs. Thus, T cell expansion but not initial
activation substantially depends on DCs in MRL.Faslpr mice.Reduced Treg Cell Proliferation and Survival
in the Absence of DCs
Several groups have reported decreased numbers and or inhib-
itory function of Treg cells in SLE patients, although not with
unanimity (Horwitz, 2008). Treg cell numbers are reported to
increase in SLE patients upon treatment with corticosteroids,
plasmapheresis, and rituximab (Horwitz, 2008). On the basis of
these findings, ameliorated disease in CD11c:DTA mice sug-
gested that there might be higher Treg cell numbers in DC-
deficient animals than in controls. However, it has recently
been proposed that DCs control the homeostatic proliferation
of Treg cells (Darrasse-Je`ze et al., 2009). In that model
decreased DC numbers led to decreased Treg cell numbers,
although another study found that DC depletion had no influence
on number and function of Treg cells in the steady state (Birnberg
et al., 2008). Hence, the effect of DC deletion on Treg cells in
murine lupus was uncertain.
Numbers of Treg cells (CD4+FoxP3+) in the spleen were mark-
edly decreased in DC-deficient mice (Figure 7A). Moreover, Ki67
staining revealed that Treg cells proliferated less in the absence
of DCs (Figure 7B). This is consistent with a model in which DCs
stimulate Treg cell proliferation, either directly or indirectly. We
further observed that expression of the IL-2 receptor constituent
CD25 was reduced on CD4+FoxP3+ T cells derived from DC-
deficient mice (Figure 7C). IL-2 is critically important for the
development, expansion, and survival of natural and induced
Treg cells (Malek, 2008). To examine whether IL-2 receptor
signaling might be reduced in Treg cells from DC-deficient
mice, we examined the expression of the IL-2-induced antia-
poptotic protein Bcl-2. We found that Bcl-2 was indeed down-
regulated in Treg cells of CD11c:DTA mice (Figure 7D).
Together, these observations indicate that DCs induce Treg
cell proliferation and support their survival under inflammatory
conditions.Spontaneous Differentiation of CD4+ and CD8+ T Cells
into IFN-g-Producing Effectors Is DC Dependent
In human SLE peripheral blood, T cells secrete large amounts of
IFN-g and have higher mRNA expression of the Th1 cell tran-
scription factor T-bet (Harigai et al., 2008). In MRL.Faslpr mice,
IFN-g hyperproduction and increased Th1 cell numbers are
a consistent finding (Prud’homme et al., 1995). Disruption of
the Ifng gene in MRL.Faslpr mice ameliorates disease (Balome-
nos et al., 1998). We asked whether DCs not only promote
T cell proliferation but also help CD4+ T cell differentiation into
Th1 cell effectors. After stimulation of total splenocytes for 4 hr
with phorbol myristate acetate (PMA) and ionomycin, we stained
for intracellular IFN-g. The frequency of IFN-g-producing cells
among CD4+ T cells derived from CD11c:DTA mice was
decreased compared to those from controls (Figure 7E). More-
over, a smaller fraction of CD8+ T cells from DC-deficient
animals produced IFN-g (Figure 7F). Thus, DCs contribute
considerably to the hyperproduction of IFN-g by promoting
Th1 cell priming and the differentiation of CD8+ T cells into
IFN-g-secreting cells.974 Immunity 33, 967–978, December 22, 2010 ª2010 Elsevier Inc.DISCUSSION
The cellular mechanisms that promote and regulate autoimmune
disease have been the subject of intense interest and study.
B cell-targeted therapies ameliorate disease severity in murine
and several human autoimmune disorders (Ahuja et al., 2007;
Do¨rner et al., 2009; Yanaba et al., 2008). As antibody-indepen-
dent mechanisms have gained support in murine and patient
studies, antigen presentation by B cells and direct T cell-medi-
ated tissue damage have come to the forefront of disease path-
ogenesis concepts. However, the role of the DC, considered the
primary APC in the immune system for pathogen recognition,
has yet to be evaluated in spontaneous, systemic autoimmunity.
Here we have addressed this question with a genetic system that
has also recently been used to evaluate induced immune
responses (Ohnmacht et al., 2009). Almost all cDCs and most
pDCs were deleted in CD11c:DTA MRL.Faslpr mice. A caveat
of ablation systems that use the promoter of the Itgax gene is
that it might be active in subpopulations of cell types that are
not DCs. We did survey other potentially affected populations
but did not notice any differences attributable to the expression
of CD11c:DTA; however, we cannot rule out subtle effects on
nontarget populations.
Although DCs promoted accumulation of T cells in secondary
lymphoid tissues, the proportion of T cells that maintained
a naive phenotype was small and barely affected by the severe
reduction in DCs achieved in the CD11c:DTA mice. If DCs were
the primary APC in the initial activation of T cells, one would have
expected a substantial naive T cell compartment in their
absence. This was not the case, in contrast to the situation in
B cell-deficient mice, which do have a markedly expanded naive
T cell compartment (Chan et al., 1999b). It is important to note
that the limited reduction in T cell activation in CD11c:DTA
mice is unlikely to be due to residual DCs. Despite extensive
depletion of cDCs, we did not see a proportional effect on main-
tenance of naive T cells, whereas given the very low frequencies
of DCs compared to T cells, DCs should have been the limiting
factor.
In contrast, the striking reduction of tissue infiltrates and
pathology implies that DCs have nonredundant role in tissue
pathogenesis. Upon interaction with infectious organisms, DCs
migrate to the draining lymph nodes, where they prime T cells.
However, the finding that T cells proliferate in situ in inflamed
kidneys leads us to hypothesize that DCs might also promote
the local expansion of T cells that were previously activated
presumably in secondary lymphoid tissues. This notion is sup-
ported by reports showing that herpes simplex virus-specific
memory CD8+ T cells are stimulated and expanded in sensory
ganglia by DCs upon reinfection (Wakim et al., 2008). In this path-
ogen response, local antigen presentation by DCs, leading to re-
activation of T cells, similarly plays an important role. The pres-
ence of small renal infiltrates in the absence of DCs indicates
that although DCs are critical for the expansion of kidney infil-
trates, they are not required to initiate them. Residual infiltrates
in CD11c:DTA mice cannot reasonably be attributed to incom-
plete DC deletion. Had there been ‘‘leakiness’’ that contributed
to residual pathology and T cell activation, then one would
have expected these renal infiltrates to contain DCs, which
they did not.
Figure 7. DCs Drive Differentiation of CD4+ and CD8+ T Cells into IFN-g-Producing Effectors and Support for Treg Cell Proliferation and
Survival
(A) Numbers of CD4+FoxP3+ T cells per spleen.
(B) Proliferation of CD4+FoxP3+ T cells determined by Ki67 staining.
(C) CD25 expression of CD4+FoxP3+ T cells.
(D) Expression of intracellular Bcl-2 of CD4+FoxP3+ T cells.
(E and F) Intracellular IFN-g staining of PMA/ionomycin-stimulated splenocytes gated on CD4+ (E) or CD8+ (F) T cells.
The histograms in (C)–(F) show representative flow cytometric data from control (black line) and CD11c:DTA (gray shaded) mice. Data in bar graphs are
represented as mean ± SEM. n = 12 for control mice and n = 9 for CD11c:DTA mice. Statistics were calculated by two-tailed Mann-Whitney U test.
**p < 0.01, ***p < 0.001.
Immunity
DCs in LupusThe quality of differentiation of T cells in secondary lymphoid
tissues was specifically affected by the presence of DCs. In
CD11c:DTA mice, CD4+ T cell activation generated fewer IFN-g-
producing Th1 and CD8+ T cells. These roles of DCs are impor-
tant, because there is a substantial IFN-g component to disease
in MRL.Faslpr mice, as well as in other murine lupus models and
in humans (Balomenos et al., 1998; Harigai et al., 2008; Schwart-
ing et al., 1998). In addition to IFN-g, type I IFNs (IFN-a/b) are
thought to be critical in SLE (Banchereau and Pascual, 2006).
One important source of type I IFNs is pDCs. Because pDCsIare also substantially deleted in CD11c:DTA mice, it is not
readily possible to distinguish their roles from cDCs. We did
attempt to selectively deplete pDCs by using the BST-2 anti-
body (Blasius et al., 2006). This was effective in BALB/c but
not MRL.Faslpr mice (data not shown), presumably owing to
global defects in FcgR-mediated cellular depletion in lupus-
prone mice (Ahuja et al., 2007). Hence, the determination of
specific pDC effects will have to await genetic approaches for
selective and long-term pDC depletion, which are not yet
available.mmunity 33, 967–978, December 22, 2010 ª2010 Elsevier Inc. 975
Immunity
DCs in LupusWe found that, in agreement with one (Darrasse-Je`ze et al.,
2009) but not two other (Birnberg et al., 2008; Ohnmacht et al.,
2009) studies, Treg cell expansion and maintenance of pheno-
type was DC dependent. Whereas on a nonautoimmune back-
ground, acute loss of DCs led to decreased numbers of Treg
cells but increased numbers of Th1 and Th17 cells, there was
instead a concomitant drop in both regulatory and inflammatory
(Th1) T cell numbers in lupus-prone mice. This emphasizes the
importance of overall context in the net effect of DCs, which
can affect multiple limbs of the immune system. The reduction
in Treg cells was a result of decreased proliferation and survival.
Unexpectedly, autoantibody, but not total serum Ig, concen-
trations were reduced in CD11c:DTA mice. We interpret this
dichotomy to mean that short-lived plasmablasts, derived from
an extrafollicular response, rather than long-lived plasma cells,
derived from germinal centers, are DC dependent. Consistent
with this, we found that the number of splenic plasmablasts
were reduced in CD11c:DTA mice. That lupus-related autoanti-
bodies such as antichromatin derive mainly from short-lived
plasmablasts has been directly documented in mice (Seo
et al., 2002; William et al., 2002) and inferred from their relatively
rapid decay upon depletion of B cells in both mice and SLE
patients (Ahuja et al., 2007; Jo´nsdo´ttir et al., 2008; Walsh and
Jayne, 2007). In contrast, total serum IgG or antimicrobial anti-
body concentrations remain stable in SLE patients after anti-
CD20 therapy (Jo´nsdo´ttir et al., 2008; Walsh and Jayne, 2007).
DCs are abundant in areas of extrafollicular plasmablast gener-
ation (Garcı´a De Vinuesa et al., 1999; William et al., 2002) and
could provide important cytokines, including IL-6, BAFF, or
APRIL, which support plasmablast differentiation, isotype
switch, and survival (Treml et al., 2009). However, whether DCs
promote plasmablast development in vivo has been questioned
(Hebel et al., 2006). Corresponding with the defect in IFN-g
generation in CD11c:DTA mice, we found a class switch defect
to IgG2a among short-lived plasmablasts. This suggests that
DC-induced T cell differentiation enables T cells to promote
class switch and possibly plasmablast generation. Such a func-
tion for T cells in extrafollicular plasmablast responses in
MRL.Faslpr mice has also been suggested by Odegard et al.
(2008). Moreover, DCs can present undegraded antigen to B
cells, arguing for direct DC-B cell interactions (Qi et al., 2006;
Bergtold et al., 2005). DCs have lectin receptors that take up
dead cell-associated antigen, which is then directed away from
the lysosomal compartment (Sancho et al., 2009). In any case,
because DCs have only a quantitative effect on autoantibodies
and plasmablast numbers, other cells such as macrophages
and B cells must be able to compensate at least in part for DCs.
Our results extend the limited published literature on the
effects of DCs on spontaneous autoimmunity. In an elegant
study in which Fas was specifically deleted in DCs in C57BL/6
mice, autoimmunity ensued, demonstrating that DCs, when dys-
regulated, can promote autoreactivity and pathology (Stranges
et al., 2007). Similarly, DC-specific deletion of SOCS-1 in DCs,
which modulates a number of proinflammatory pathways, re-
sulted in autoimmunity (Hanada et al., 2003). In these types of
studies, DCs are experimentally made abnormal; by definition,
DCs must be upstream of all other observed pathology in such
experimental setups. In our study, in the context of global abnor-
mality, via the ablation approach, we were able to see what DCs976 Immunity 33, 967–978, December 22, 2010 ª2010 Elsevier Inc.are required for, rather than what they can do. In this case, DCs
could have been either upstream or downstream of the activa-
tion of other aspects of the immune system. In this way we
were able to observe unexpected roles for DCs in expanding
preactivated T cells in secondary lymphoid and probably periph-
eral tissues.
It is interesting that, despite the fact that DCs promote autoim-
munity inMRL.Faslprmice and in the above-mentioned studies of
dysregulated DCs on a C57BL/6 background, deletion of DCs
per se in C57BL/6 mice in one case (Ohnmacht et al., 2009),
but not another (Birnberg et al., 2008), led to increased autoreac-
tivity. Differences in background genes or environmental factors
(e.g., environmental organisms) might account for the contradic-
tory results in those two studies. Another study assigned a
regulatory role to pDCs in ongoing insulitis in a diabetes model
(Saxena et al., 2007). This highlights the context-dependent
role of DCs; clearly, we found that DCs function to promote
rather than regulate disease in the setting of established predis-
position to lupus. Although there is much more work to do in
defining the roles of DCs in autoimmunity, including DC-T cell
and DC-B cell interactions, our current data validate DCs as
a potential new therapeutic target in autoimmunity as well as
provide direction for future studies.EXPERIMENTAL PROCEDURES
Mice
CD11c-Cre BAC transgenic C57BL/6 mice (Caton et al., 2007) and Rosa26-
eGFP-DTA C57BL/6 mice (Ivanova et al., 2005) were backcrossed (13 and 9
times, respectively) onto the Fas-deficient, lupus-prone MRL-MpJ-Faslpr/J
strain (Jackson Laboratory). Homozygosity for the H2k haplotype and the lpr
mutation was verified by PCR. The Rosa26-eGFP-DTA locus contains the
gene for the diphtheria toxin a chain (DTA) that is preceded by a loxP-flanked
STOP cassette so that expression of the toxin is restricted to those cells ex-
pressing Cre recombinase. Both strains were then intercrossed to generate
constitutively DC-deficient CD11c-Cre+Rosa26-eGFP-DTA+ mice. CD11c-
Cre+, Rosa26-eGFP-DTA+, and wild-type littermates were used as controls.
The three types of control mice were found to be indistinguishable in all exper-
iments performed. Langerin-DTA FVB/N mice (Kaplan et al., 2005) were
crossed to MRL-MpJ-Faslpr/2J mice. F1 offspring were intercrossed to
generate Langerin-DTA+ and control Langerin-DTA Fas-deficient (Faslpr/lpr)
F2 mice. For BrdU studies, wild-type MRL-MpJ-Faslpr/J mice were injected
with 3mg BrdU i.p. and sacrificed 2 hr later. All animals were maintained under
specific-pathogen-free (SPF) conditions and handled according to protocols
approved by the Yale Institutional Animal Care and Use Committee.Flow Cytometry
Surface staining was performed in ice-cold PBS with 3% calf serum in the
presence of FcR blocking antibody 2.4G2. Antibody clones used for surface
staining were: anti-BST2 (927), anti-CD4 (GK1.5), anti-CD8 (TIB 105), anti-
CD11b (M1/70), anti-CD11c (N418), anti-CD19 (1D3), anti-CD22 (Cy34.1),
anti-CD25 (PC61), anti-CD44 (1M7), anti-CD138 (281-2), anti-F4/80 (BM8),
anti-I-A/I-E (M5/114), anti-Ly6G/Ly6C (RB6-8C5), and anti-TCRb (H57-597).
Intracellular staining was performed with the BD Cytofix/Cytoperm and
Perm/Wash buffers or, for intracellular FoxP3 staining, the eBioscience
FoxP3 staining buffer set. For intracellular cytokine staining, 4 3 106 spleno-
cytes were cultured for 4 hr at 37C in 24-well plates in 2 ml culture medium
containing ionomycin (750 ng/ml) and PMA (20 ng/ml). For the last 2 hr brefel-
din A (10 mg/ml) was added to the cultures. Antibody clones used for intracel-
lular staining were: anti-activated caspase 3 (C92-605), anti-Bcl-2 (3H11), anti-
FoxP3 (FJK-16), anti-IFN-g (XMG1.2), anti-kappa (187.1), and anti-Ki67 (SP6).
Ethidium monoazide (EMA) was used for live-dead discrimination. Cells were
analyzed on a LSRII instrument (BD).
Immunity
DCs in LupusImmunofluorescence
Kidneys were fixed in 0.7% paraformaldehyde-lysine-periodate (PLP) solution
and frozen in OCT (TissueTek) after dehydration in 30% sucrose solution.
Cryostat sections (7 mm) were stained with the following antibodies: Alexa
Fluor (AF) 647-labeled anti-CD11c (N418), AF488-labeled anti-CD4 (GK1.5),
and rabbit anti-Ki67 (SP6) followed by AF568-labeled goat anti-rabbit IgG (In-
vitrogen). To detect glomerular immune complexes, sections were stained
with AF555-labeled goat anti-mouse IgG (highly cross-adsorbed, Southern
Biotech), rat anti-mouse C3 (RmC11H9), followed by AF647-labeled goat
anti-rat IgG (cross-adsorbed against mouse IgG, Southern Biotech). BrdU
staining was performed as described previously (Hauser et al., 2007). Spleens
were frozen in OCT and cryostat sections fixed in acetone. Spleen sections
were stained with biotinylated anti-CD4 (GK1.5) and AF647-labeled anti-
CD169 (MOMA-1) or with AF647-labeled anti-CD4 and biotinylated anti-
CD209b (ER-TR9). Streptavidin-AF555 (Invitrogen) was used as a secondary
reagent. Epidermal sheets were prepared as described previously (Kaplan
et al., 2005). Epidermal sheets were stained with biotinylated rat anti-mouse
I-A/I-E (M5/114) followed by AF555-conjugated streptavidin (Invitrogen).
Tissues were mounted in Prolong Gold antifade mounting medium (Invitrogen,
with or without DAPI). HEp-2 immunofluorescence assays (Antibodies Inc.)
were performed as previously described (Christensen et al., 2005) with serum
diluted at 1:100. Images were captured on an Olympus BX-40, a Nikon Eclipse
Ti-U, or for confocal images on a Zeiss LSM 510microscope and processed in
Adobe Photoshop.ELISA and Luminex
Antinucleosome ELISA was performed essentially as previously described
(Nickerson et al., 2010). Specific antibodies were detected with alkaline phos-
phatase-conjugated goat anti-mouse IgG or IgM (Southern Biotech). The
monoclonal antibody PL2-3 (Losman et al., 1993) was used as a standard
for IgG antinucleosome measurement and 3H9/Vk1 (Shlomchik et al., 1987)
for IgM antinucleosome. Anti-Sm and anti-IgG2a rheumatoid factor concen-
trations were determined by ELISA as previously described (Christensen
et al., 2005; Nickerson et al., 2010). Serum concentrations of individual Ig iso-
types were measured by Luminex assay (Millipore) according to the manufac-
turer’s protocol.Evaluation of Clinical Disease
For kidney disease, formalin-fixed and paraffin-embedded sections, stained
with either H&E or PAS, were scored for glomerular and interstitial nephritis
by a pathologist (M.K.) who was blinded to the genotype of the mice. H&E-
stained slides were photographed to determine the total area of renal perivas-
cular infiltrates relative to the total area of the kidney section via ImageJ soft-
ware (http://rsb.info.nih.gov/ij/). Proteinuria was measured with Bayer Albustix
reagent strips. Mice were classified as positive for dermatitis upon develop-
ment of typical lesions on the dorsum of the neck and back.SUPPLEMENTAL INFORMATION
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